Patents by Inventor Hermann Wagner
Hermann Wagner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9458234Abstract: The present invention is directed to a cross-reactive antibody, which specifically inhibits or blocks the mammalian Toll-like receptor 2 (TLR2)-mediated immune cell activation. The invention is further directed to an isolated nucleic acid or vector coding for the variable regions of the heavy and/or light chain of the antibody. It is further providing a pharmaceutical composition comprising the antibody, nucleic acid or vector and is directed to the use of the composition in the prevention and/or treatment of inflammatory processes or any other process induced by bacterial infection, trauma, or chronic inflammation, or for the prevention and/or treatment of bacteriaemia or sepsis.Type: GrantFiled: December 19, 2013Date of Patent: October 4, 2016Assignees: Technische Universitat Munchen, Amgen Inc.Inventors: Carsten Juergen Kirschning, Guangxun Meng, Hermann Wagner
-
Patent number: 9428536Abstract: Compositions and methods relating to immunostimulatory RNA oligomers are provided. The immunostimulatory RNA molecules are believed to represent natural ligands of one or more Toll-like receptors, including Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8). The compositions and methods are useful for stimulating immune activation. Methods useful for screening candidate immunostimulatory compounds are also provided.Type: GrantFiled: January 21, 2014Date of Patent: August 30, 2016Assignee: Zoetis Belgium SAInventors: Grayson B. Lipford, Stefan Bauer, Hermann Wagner
-
Publication number: 20140343256Abstract: The present invention is directed to a cross-reactive antibody, which specifically inhibits or blocks the mammalian Toll-like receptor 2 (TLR2)-mediated immune cell activation. The invention is further directed to an isolated nucleic acid or vector coding for the variable regions of the heavy and/or light chain of said antibody. It is further providing a pharmaceutical composition comprising said antibody, nucleic acid or vector and is directed to the use of said composition in the prevention and/or treatment of inflammatory processes or any other process induced by bacterial infection, trauma, or chronic inflammation, or for the prevention and/or treatment of bacteriaemia or sepsis.Type: ApplicationFiled: December 19, 2013Publication date: November 20, 2014Applicant: Technische Universitaet MunchenInventors: Carsten Juergen Kirschning, Guangxun Meng, Hermann Wagner
-
Publication number: 20140135487Abstract: Compositions and methods relating to immunostimulatory RNA oligomers are provided. The immunostimulatory RNA molecules are believed to represent natural ligands of one or more Toll-like receptors, including Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8). The compositions and methods are useful for stimulating immune activation. Methods useful for screening candidate immunostimulatory compounds are also provided.Type: ApplicationFiled: January 21, 2014Publication date: May 15, 2014Applicant: COLEY PHARMACEUTICAL GMBHInventors: GRAYSON B. LIPFORD, STEFAN BAUER, HERMANN WAGNER
-
Patent number: 8658607Abstract: Compositions and methods relating to immunostimulatory RNA oligomers are provided. The immunostimulatory RNA molecules are believed to represent natural ligands of one or more Toll-like receptors, including Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8). The compositions and methods are useful for stimulating immune activation. Methods useful for screening candidate immunostimulatory compounds are also provided.Type: GrantFiled: March 3, 2006Date of Patent: February 25, 2014Assignee: Zoetis BelgiumInventors: Grayson B. Lipford, Stefan Bauer, Hermann Wagner
-
Patent number: 8623353Abstract: The present invention is directed to a cross-reactive antibody that specifically inhibits or blocks mammalian Toll-like receptor 2 (TLR2)-mediated immune cell activation. The invention is further directed to an isolated nucleic acid or vector coding for the variable regions of the heavy and/or light chain of such an antibody. Also provided is a pharmaceutical composition comprising such an antibody, or a nucleic acid or vector encoding it. Further provided are methods of use of such compositions in the prevention and/or treatment of inflammatory processes or any other process induced by bacterial infection, trauma, or chronic inflammation, or for the prevention and/or treatment of bacteriaemia or sepsis.Type: GrantFiled: September 23, 2004Date of Patent: January 7, 2014Assignees: Technische Universitat Munchen, Amgen Inc.Inventors: Carsten Juergen Kirschning, Guangxun Meng, Hermann Wagner
-
Patent number: 8298782Abstract: The present invention relates to a new method for reversible staining and functional isolation or characterization of cells, e.g. antigen-specific T cells. With this technique, the original functional status of cells can be substantially maintained after their identification and purification. Thus, this new method is of broad benefit for basic research and clinical applications.Type: GrantFiled: July 26, 2010Date of Patent: October 30, 2012Assignee: IBA GmbHInventors: Dirk H. Busch, Hermann Wagner
-
Publication number: 20120199178Abstract: A raw module is provided that includes a substrate, a front electrode layer, a semiconductor layer, and a rear electrode layer. The layers are separated by structuring trenches into sub cells, which are electrically connected in series in an interconnection direction. The module has a first separating region separating the module into two sub modules along a first separating line running in the interconnection direction. The separating region includes: a first and a second isolation trench running parallel to one another and on both sides of the first separating line in the interconnection direction; a third isolation trench extending from the first isolation trench at least as far as the first separating line but not as far as the second isolation trench; and a fourth isolation trench extending from the second isolation trench at least as far as the separating line but not as far as the first isolation trench.Type: ApplicationFiled: February 3, 2012Publication date: August 9, 2012Applicant: SCHOTT SOLAR AGInventors: Hermann Wagner, Walter Psyk, Peter Lechner
-
Publication number: 20120164782Abstract: A photovoltaic thin-film module is provided that includes a substrate on which a transparent front electrode layer, a semiconductor layer, and a rear electrode layer are deposited as functional layers, which are provided with cell dividing lines for forming series-connected cells. The functional layers are ablated using a laser in the edge area. An insulation dividing line is formed in the edge region for the insulation between the front and rear electrode layers using a second laser. The ablation of the functional layers and the forming of the insulation dividing line are performed jointly in one step.Type: ApplicationFiled: May 12, 2010Publication date: June 28, 2012Inventor: Hermann Wagner
-
Patent number: 8153141Abstract: Compositions and methods relating to immunostimulatory RNA oligomers are provided. The immunostimulatory RNA molecules are believed to represent natural ligands of one or more Toll-like receptors, including Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8). The compositions and methods are useful for stimulating immune activation. Methods useful for screening candidate immunostimulatory compounds are also provided.Type: GrantFiled: April 4, 2003Date of Patent: April 10, 2012Assignee: Coley Pharmaceutical GmbHInventors: Grayson Lipford, Stefan Bauer, Hermann Wagner
-
Publication number: 20110070605Abstract: The present invention relates to a new method for reversible staining and functional isolation or characterization of cells, e.g. antigen-specific T cells. With this technique, the original functional status of cells can be substantially maintained after their identification and purification. Thus, this new method is of broad benefit for basic research and clinical applications.Type: ApplicationFiled: July 26, 2010Publication date: March 24, 2011Inventors: Dirk H. BUSCH, Hermann WAGNER
-
Publication number: 20100304526Abstract: Photovoltaic module comprising a transparent substrate (1), a transparent front electrode layer (2), a semiconducting layer (3) of microcrystalline or micromorphous silicon and a rear electrode layer (4), said layers structured to form cells (C1, C2, C3) electrically separated by separating lines (5, 6, 7) and electrically connected in series. A laser beam (14) is used to generate at least in rear electrode layer (4) separating line sections (18, 18?) interconnected to form continuous separating lines (7) by connecting sections (19, 20) extending at an angle (?) to separating line sections (18, 18?).Type: ApplicationFiled: May 20, 2010Publication date: December 2, 2010Inventors: Walter Psyk, Joerg Reuner, Hermann Wagner
-
Patent number: 7820379Abstract: The invention pertains to murine TLR9 and related TLR9s which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR9. The invention further relates to methods of using such murine and non-murine TLR9 nucleic acids and polypeptides, especially in methods for screening for agonists and antagonists of immunostimulatory CpG nucleic acids. Also included are murine TLR9 inhibitors which inhibit murine TLR9 activity by inhibiting the expression or function of murine TLR9. In a further aspect the present invention pertains to murine TLR7 and murine TLR8, as well as related TLR7 and TLR8 molecules which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR7 and TLR8.Type: GrantFiled: March 18, 2005Date of Patent: October 26, 2010Assignee: Coley Pharmaceutical GmbHInventors: Stefan Bauer, Grayson B. Lipford, Hermann Wagner
-
Patent number: 7776562Abstract: The present invention relates to a new method for reversible staining and functional isolation or characterization of cells, e.g. antigen-specific T cells. With this technique, the original functional status of cells can be substantially maintained after their identification and purification. Thus, this new method is of broad benefit for basic research and clinical applications.Type: GrantFiled: December 28, 2001Date of Patent: August 17, 2010Assignee: IBA GmbHInventors: Dirk H. Busch, Hermann Wagner
-
Publication number: 20090060927Abstract: The present invention relates to pharmaceutical compositions comprising at least one fragment of a polynucleotide, preferably at least one antigen, and optionally a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention was found that the introduction of the pharmaceutical composition into vertebrates will achieve regulation of growth, induction of cellular transcription and translation, protein synthesis, protein expression or protein secretion. The pharmaceutical compositions are useful in vaccination protocols but also in any other therapeutic situation in which immunomodulation is of benefit, such as sub-optimal immune responses, reaction to pathogens, tolerance or autoimmunity.Type: ApplicationFiled: March 26, 2004Publication date: March 5, 2009Applicant: Coley Pharmaceutical GmbHInventors: Hermann Wagner, Grayson Lipford, Klaus Heeg
-
Publication number: 20080113929Abstract: Compositions and methods are provided for enhancing delivery of therapeutic agents. More specifically, compositions and methods are provided for improving antigen delivery to antigen-presenting cells. Conjugates between abasic oligonucleotides and antigen are provided, along with methods for their use in vaccination and in the treatment of cancer, infection, and allergy and asthma. Also provided are conjugates between abasic oligonucleotides and various immunostimulatory nucleic acids, including CpG oligonucleotides, as well as methods of use thereof. Also provided are conjugates between abasic oligonucleotides and various other agonists and antagonists of immunostimulation, as well as methods of use thereof.Type: ApplicationFiled: June 8, 2005Publication date: May 15, 2008Applicant: Coley Pharmaceutical GmbHInventors: Grayson B. Lipford, Alexandra Forsbach, Eugen Uhlmann, Hermann Wagner
-
Publication number: 20070184465Abstract: The invention relates to methods for regulating hematopoiesis using CpG containing oligonucleotides. In particular, the invention relates to methods of treating thrombopoiesis and anemia by regulating hematopoiesis. The invention also relates to methods of regulating immune system remodeling by administering CpG oligonucleotides to control hematopoiesis.Type: ApplicationFiled: November 10, 2006Publication date: August 9, 2007Applicant: Coley Pharmaceutical GmbHInventors: Hermann Wagner, Grayson Lipford
-
Publication number: 20060172966Abstract: Compositions and methods relating to immunostimulatory RNA oligomers are provided. The immunostimulatory RNA molecules are believed to represent natural ligands of one or more Toll-like receptors, including Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8). The compositions and methods are useful for stimulating immune activation. Methods useful for screening candidate immunostimulatory compounds are also provided.Type: ApplicationFiled: March 3, 2006Publication date: August 3, 2006Applicant: Coley Pharmaceutical GmbHInventors: Grayson Lipford, Stefan Bauer, Hermann Wagner
-
Patent number: 7001890Abstract: The present invention relates to pharmaceutical compositions comprising at least one fragment of a polynucleotide, preferably at least one antigen, and optionally a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention was found that the introduction of the pharmaceutical composition into vertebrates will achieve regulation of growth, induction of cellular transcription and translation, protein synthesis, protein expression or protein secretion. The pharmaceutical compositions are useful in vaccination protocols but also in any other therapeutic situation in which immunomodulation is of benefit, such as sub-optimal immune responses, reaction to pathogens, tolerance or autoimmunity.Type: GrantFiled: January 23, 1998Date of Patent: February 21, 2006Assignee: Coley Pharmaceutical GmbHInventors: Hermann Wagner, Grayson Lipford, Klaus Heeg
-
Patent number: 6943240Abstract: The invention pertains to murine TLR9 and related TLR9s which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR9. The invention further relates to methods of using such murine and non-murine TLR9 nucleic acids and polypeptides, especially in methods for screening for agonists and antagonists of immunostimulatory CpG nucleic acids. Also included are murine TLR9 inhibitors which inhibit murine TLR9 activity by inhibiting the expression or function of murine TLR9. In a further aspect the present invention pertains to murine TLR7 and murine TLR8, as well as related TLR7 and TLR8 molecules which include murine-specific amino acids, as well as nucleic acids which encode those polypeptides. The present invention also includes fragments and biologically functional variants of the murine TLR7 and TLR8.Type: GrantFiled: September 17, 2001Date of Patent: September 13, 2005Assignee: Coley Pharmaceuticals GmbHInventors: Stefan Bauer, Grayson Lipford, Hermann Wagner